Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy
Trial details
- Registry ID
- NCT03340675
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Oral Ifetroban in Subjects With Duchenne Muscular DystrophyNCT03340675 | Cumberland Pharmaceuticals | Phase 2 | Completed | 2024-03-06Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |